AC Immune SA (FRA:IMR)

Germany flag Germany · Delayed Price · Currency is EUR
2.365
-0.075 (-3.07%)
At close: Dec 4, 2025
-20.64%
Market Cap 244.35M
Revenue (ttm) 4.67M
Net Income (ttm) -76.82M
Shares Out n/a
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 1,146
Open 2.365
Previous Close 2.440
Day's Range 2.365 - 2.365
52-Week Range 1.244 - 3.315
Beta n/a
RSI 43.42
Earnings Date Mar 13, 2026

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 172
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol IMR
Full Company Profile

Financial Performance

In 2024, AC Immune's revenue was 27.31 million, an increase of 84.51% compared to the previous year's 14.80 million. Losses were -50.92 million, -6.12% less than in 2023.

Financial numbers in CHF Financial Statements

News

There is no news available yet.